PEGBIO voluntarily dissolves its subsidiary Shanghai MaiJi to focus on core business and streamline operations

AASTOCKS
2025.11.03 09:29

PEGBIO CO (02565.HK) announced that it has applied for voluntary dissolution of its non-wholly-owned subsidiary Shanghai MaiJi. The company stated that Shanghai MaiJi is engaged in the research and development of the peptide hormone GLP-2, and the dissolution is aimed at focusing on core business and streamlining operations. After the dissolution, the company will continue to develop its core products in the fields of metabolism and weight loss treatment. Therefore, the dissolution will not have an adverse impact on the overall business operations and financial condition of the company or the group

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.